Skip to main content

Advertisement

SpringerLink
Log in

Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy

  • Clinical Trail
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Purpose: The aim of this study was to identify the predictors of the response to doxorubicin plus cyclophosphamide in patients with recurrent breast cancer (RBC) previously treated with anthracycline-containing regimens in a neoadjuvant or adjuvant setting.

Method: Between December 1993 and October 2005, 664 patients had received combined doxorubicin plus cyclophosphamide chemotherapy (doxorubicin, 40 mg/m2, iv on day 1; cyclophosphamide, 500 mg/m2, iv on day 1, every 21 days) for RBC at our institution. In this study, we retrospectively analyzed the efficacy of doxorubicin plus cyclophosphamide in 99 of these 664 RBC patients who had also previously been administered an anthracycline-based chemotherapy in a neoadjuvant or adjuvant setting.

Results: The median cumulative dose of the previously administered anthracycline was 156 mg/m2. The median disease-free interval (DFI) and median anthracycline-free interval were 33.8 and 43.7 months, respectively. The overall response rate to doxorubicin plus cyclophosphamide therapy was 38.4% (95% CI; range, 28.8–48.0%). The median time to progression and overall survival were 6.2 and 17.5 months, respectively. The results of a multivariate logistic regression analysis revealed a significant association of the response to doxorubicin plus cyclophosphamide therapy with the DFI (P = 0.02); human epidermal receptor type 2 (HER2) status also tended to affect the response rate, however the association was not statistically significant (P = 0.06).

Conclusion: DFI and HER2 status may be associated with the response to repeat utilization of anthracycline-containing regimens in RBC patients also treated previously with anthracycline-containing chemotherapeutic regimens in a neoadjuvant or adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930–942

    Article  Google Scholar 

  2. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493

    PubMed  CAS  Google Scholar 

  3. Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125

    Article  PubMed  CAS  Google Scholar 

  4. Beyer J, Kramar A, Mandanas R et al (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 14:2638–2645

    PubMed  CAS  Google Scholar 

  5. Chua YJ, Steer C, Yip D (2004) Recent advances in management of small-cell lung cancer. Cancer Treat Rev 30:521–543

    Article  PubMed  CAS  Google Scholar 

  6. Joensuu H, Holli K, Heikkinen M et al (1998) Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 16:3720–3730

    PubMed  CAS  Google Scholar 

  7. World Health Organization (1979) WHO handbook for reporting result of cancer treatment: offset publication 48. World Health Organization, Geneva

    Google Scholar 

  8. Buzdar AU, Legha SS, Hortobagyi GN et al (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47:2798–2802

    Article  PubMed  CAS  Google Scholar 

  9. Ro J, Fraschini G, Frye D et al (1989) Reutilization of doxorubicin in patients with progressive metastatic breast cancer. Int J Exp Clin Chemother 2:234–238

    Google Scholar 

  10. Martin M, Garcia-Donas J, Casado A et al (2004) Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure. Clin Breast Cancer 5:353–357

    PubMed  CAS  Google Scholar 

  11. Overmoyer B, Silverman P, Holder LW et al (2005) Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer 6:150–157

    Article  PubMed  CAS  Google Scholar 

  12. Fabi A, Ferretti G, Papaldo P et al (2006) Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients. Cancer Chemother Pharmacol 57:615–623

    Article  PubMed  CAS  Google Scholar 

  13. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401–2408

    PubMed  CAS  Google Scholar 

  14. Tinari N, Lattanzio R, Natoli C et al (2006) Changes of topoisomerase II alpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin Cancer Res 12:1501–1506

    Article  PubMed  CAS  Google Scholar 

  15. Isola JJ, Tanner M, Holli K et al (2000) Amplification of topoisomerase II alpha is a strong predictor of response to epirubicin-based chemotherapy in HER2/neu positive metastatic breast cancer. In: Abstracts of the 23rd annual San Antonio breast cancer symposium, San Antonio, 6–9 December 2000

  16. Di Leo A, Gancberg D, Larsimont D et al (2002) HER2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107–1116

    PubMed  CAS  Google Scholar 

  17. Pritchard KI, Shepherd LE, O’Malley FP et al (2006) HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103–2111

    Article  PubMed  CAS  Google Scholar 

  18. Salmon DJ, Godolphin W, Jones LA et al (1987) Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 235:177–182

    Article  Google Scholar 

  19. Batist G, Ramakrishnan G, Rao CS et al (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposomal-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 19:1444–1454

    PubMed  CAS  Google Scholar 

  20. Biganzoli L, Cufer T, Bruning P et al (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114–3121

    Article  PubMed  CAS  Google Scholar 

  21. Katsumata N, Minami H, Aogi K et al (2005) Phase III trial of doxorubicin/cyclophosphamide, docetaxel, and alternating AC and D as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial. In: Abstracts of the 41st annual meeting of American Society of Clinical Oncology, Orlando, 13–17 May 2005. Proc Am Soc Clin Oncol 23:521A

  22. Swain SM, Whaley FS, Gerber MC et al (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333–1340

    PubMed  CAS  Google Scholar 

  23. Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717

    Google Scholar 

  24. Praga C, Beretta G, Vigo PL et al (1979) Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 63:827–834

    PubMed  CAS  Google Scholar 

  25. Krischer JP, Epstein S, Cuthbertson DD et al (1997) Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the pediatric oncology group experience. J Clin Oncol 15:1544–1552

    PubMed  CAS  Google Scholar 

  26. Legha SS, Benjamin RS, Mackay B et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133–139

    PubMed  CAS  Google Scholar 

  27. Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin North Am 8:431–450

    PubMed  CAS  Google Scholar 

  28. Schwartz RG, McKenzie WB, Alexander J et al (1987) Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82:1109–1118

    Article  PubMed  CAS  Google Scholar 

  29. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the Ministry of Health, Labour and Welfare.

Author information

Authors and Affiliations

  1. Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Kan Yonemori, Noriyuki Katsumata, Koji Matsumoto, Tsutomu Kouno, Chikako Shimizu, Masashi Ando & Yasuhiro Fujiwara

  2. Division of Biostatistics, Kitasato University Graduate School, 5-9-1 Shirokane, Minato-ku, Tokyo, Japan

    Masayuki Kaneko, Hajime Uno & Masahiro Takeuchi

Authors
  1. Kan Yonemori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noriyuki Katsumata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masayuki Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hajime Uno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koji Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsutomu Kouno
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chikako Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masashi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masahiro Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yasuhiro Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kan Yonemori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yonemori, K., Katsumata, N., Kaneko, M. et al. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. Breast Cancer Res Treat 103, 313–318 (2007). https://doi.org/10.1007/s10549-006-9384-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9384-8

Keywords

Search

Navigation